By Appbay Technologies
A unified platform doesn’t mean unified risk.
The Move: One Platform, Three Domains
A life sciences company recently launched a unified agentic AI platform spanning three structurally different domains: clinical, commercial, and real-world data. It’s a genuinely ambitious integration-one architecture, covering everything from patient-safety-critical clinical decisions to client-facing commercial ones.
“Unified” and “agentic” together imply something specific: autonomous action across domains with very different regulatory stakes. A clinical-domain error carries consequences a commercial-domain one simply doesn’t-but one platform now spans both.
The Hidden Problem: One Governance Layer,
Two Very Different Stakes
Clinical decisions need patient-safety-grade oversight. Commercial decisions don’t. Here’s where that tension actually plays out:
- Clinical domain, highest stakes-regulated, patient-safety-critical, zero margin for under-governance
- Commercial domain, different rules-client-facing, less regulated, but sharing the same underlying platform
- One platform, mismatched governance-a single architecture has to satisfy the strictest domain’s requirements, or risk under-governing the others
- Under-governed domain, real exposure-an agentic AI action taken without domain-appropriate governance creates risk disproportionate to where it happened
Why does this exist? Unifying agentic AI across a highly regulated domain and a much less regulated one means the platform has to be built for the strictest requirement across the board -not the average. Get that calibration wrong, and either the commercial domain gets needlessly constrained, or the clinical domain gets dangerously under-governed.
Why This Matters Now
The platform has launched. The leadership-level question that follows isn’t whether it works-it’s whether every domain is actually governed to its own standard, not to some average across all three.
“Is this platform governed per domain-or governed at the average, leaving the strictest domain under-protected?”
That question carries real weight for a specific reason: the growth this platform supports isn’t happening in a vacuum. It’s occurring despite named client cautiousness, which invites more scrutiny on execution reliability, not less. There’s also a second, more existential pressure sitting underneath all of it-the company is actively defending its AI strategy against the concern that the technology could displace its own core services rather than strengthen them. A governance failure in the wrong domain wouldn’t just be an operational miss. It would hand that exact narrative more weight.
An Open Question, Not a Pitch
This is genuinely interesting territory-but it sits outside anything Appbay has direct experience in. Appbay’s Appian workflow expertise is specific to financial-crime and compliance workflows: AML, KYC, lending, and compliance orchestration for financial institutions. Life sciences, clinical trial governance, and healthcare-regulatory AI are a different domain entirely, with different stakes and a different expertise bar.
So instead of forcing a solution we’re not positioned to credibly offer, here’s the honest version of what a domain-differentiated governance model would need to solve for, in principle:
- AI action tagged by domain at the point of execution, not after the fact
- Domain-specific risk thresholds applied-clinical held to a different bar than commercial
- Gap flagging when an action doesn’t meet its domain’s required standard
- Domain expert review-someone with the right expertise for that specific domain, not a generalist
- An orchestrated approval workflow, calibrated per domain rather than uniformly
- A full audit trail, proving governance was applied correctly, domain by domain
Whether that’s built in-house, by a specialized life sciences AI governance partner, or some other route -that’s genuinely not ours to prescribe here.
This Pattern Isn’t Unique to Life Sciences
This is worth watching well beyond one company or one industry. Any organization unifying AI capability across domains with meaningfully different regulatory stakes-healthcare, financial services, critical infrastructure-will eventually face the same question: is the platform governed per domain, or governed at the average? The organizations getting ahead of it aren’t waiting for a governance gap to surface the hard way.
Curious, Not Pitching
If you’re working in life sciences, healthcare AI, or any cross-domain platform governance space and this tension sounds familiar-we’d genuinely like to hear how you’re approaching it.
Drop a comment or send a message-this one’s about the conversation, not a proposal.
